| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 15 | 27 | 81 | 87 |
| Cost of revenue | 0 | 0 | 20 | 18 |
| Research and development | 3,513 | 3,514 | 1,481 | 4,471 |
| General and administrative | 2,150 | 2,377 | 2,656 | 3,413 |
| Total operating expenses | 5,663 | 5,891 | 4,157 | 7,902 |
| Loss from operations | -5,648 | -5,864 | -4,076 | -7,815 |
| Interest income | 40 | 62 | 81 | 127 |
| Interest expense | 649 | 679 | 608 | 1,022 |
| Change in fair value of common stock warrant liabilities | 1,728 | 515 | -2,510 | -697 |
| Change in fair value of derivative liabilities | -797 | -439 | 1,147 | - |
| Change in fair value of clene nanomedicine contingent earn-out liability | 0 | 0 | - | - |
| Change in fair value of initial stockholders contingent earn-out liability | 0 | 0 | - | - |
| Research and development tax credits and unrestricted grants | 5 | 16 | 195 | 27 |
| Total other income (expense), net | -3,129 | -1,555 | 3,325 | -171 |
| Net loss before income taxes | -8,777 | -7,419 | -751 | -7,986 |
| Income tax expense | 0 | 0 | - | - |
| Net loss | -8,777 | -7,419 | -751 | -7,986 |
| Unrealized loss on available-for-sale securities | 0 | 0 | - | - |
| Foreign currency translation adjustments | 1 | 63 | 15 | 52 |
| Unrealized gain (loss) on available-for-sale securities | - | - | - | 1 |
| Total other comprehensive income | 1 | 63 | 15 | 53 |
| Comprehensive loss | -8,776 | -7,356 | -736 | -7,933 |
| Net loss per share basic and diluted (in dollars per share) | -0.85 | -0.78 | -0.09 | -1.22 |
| Weighted average common shares used to compute basic and diluted net loss per share (in shares) | 10,284,674 | 9,523,592 | 8,824,673 | 6,557,839 |
Clene Inc. (CLNN)
Clene Inc. (CLNN)